GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Great Novel Therapeutics Biotech & Medicals (ROCO:7427) » Definitions » COGS-to-Revenue

Great Novel Therapeutics Biotech & Medicals (ROCO:7427) COGS-to-Revenue : 25.40 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Great Novel Therapeutics Biotech & Medicals COGS-to-Revenue?

Great Novel Therapeutics Biotech & Medicals's Cost of Goods Sold for the six months ended in Dec. 2023 was NT$2.24 Mil. Its Revenue for the six months ended in Dec. 2023 was NT$0.09 Mil.

Great Novel Therapeutics Biotech & Medicals's COGS to Revenue for the six months ended in Dec. 2023 was 25.40.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Great Novel Therapeutics Biotech & Medicals's Gross Margin % for the six months ended in Dec. 2023 was -2,439.77%.

Great Novel Therapeutics Biotech & Medicals COGS-to-Revenue Historical Data

The historical data trend for Great Novel Therapeutics Biotech & Medicals's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Great Novel Therapeutics Biotech & Medicals COGS-to-Revenue Chart

Great Novel Therapeutics Biotech & Medicals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
COGS-to-Revenue
Get a 7-Day Free Trial 0.99 - 0.55 0.14 0.46

Great Novel Therapeutics Biotech & Medicals Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.59 0.14 - - 25.40

Great Novel Therapeutics Biotech & Medicals COGS-to-Revenue Calculation

Great Novel Therapeutics Biotech & Medicals's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=2.235 / 4.85
=0.46

Great Novel Therapeutics Biotech & Medicals's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=2.235 / 0.088
=25.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Great Novel Therapeutics Biotech & Medicals  (ROCO:7427) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Great Novel Therapeutics Biotech & Medicals's Gross Margin % for the six months ended in Dec. 2023 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 2.235 / 0.088
=-2,439.77 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Great Novel Therapeutics Biotech & Medicals COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Great Novel Therapeutics Biotech & Medicals's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Great Novel Therapeutics Biotech & Medicals (ROCO:7427) » Definitions » COGS-to-Revenue
Comparable Companies
TPE:1733 ROCO:4194 ROCO:4724 ROCO:6564 ROCO:4130 ROCO:6580 ROCO:4168 ROCO:4911 ROCO:6879 ROCO:6926 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
No.3, Park Street, Room WR-06, 17th Floor, Nangang District, Taipei, TWN, 11503
Website
http://www.gntbm.com.tw
Great Novel Therapeutics Biotech & Medicals focuses on drug development to treat advanced cancer. The new drugs ranging from epigenetic modulators, a combination of tumor microenvironment-regulating agents, epigenetic immuno-modulators, to the protein degradation drugs targeting HDACs 1, 2, and 3, are in a developing pipeline. These drugs focus on the field of epigenetics, for the demand of clinical unmet needs in advanced and refractory cancers.

Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Headlines

No Headlines